Lexicon announces data from four stories of sotagliflozin to be delivered

Lexicon (LXRX) Pharmaceuticals announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s, AHAm Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois. One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages.